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ABSTRACT
￿
Bindingof ' 251-labeled insulin to the surface receptors of Cloudman S-91 mouse melanoma
cells (CCL 53.1) was studied at various phases (M, G1, S, and G2) in the cell cycle. Insulin-binding
activity was persistently present during the cell cycle but the highest activity was noted at the S-
phase. The insulin once bound to the cell surface receptors at any phase of the cell cycle was
internalized and degraded, presumably through a lysosomal pathway. Insulin-binding activity of
melanoma cells was not affected by melanocyte-stimulating hormone.
Among the polypeptide hormones, insulin is one of the most
complex in action because it plays diverse functions in the
regulation of carbohydrate, amino acid, and fat metabolism (6,
21). Insulin is also known to stimulate DNA synthesis and
promote cellular growth in many cell types in culture through
modulating a number of cellular processes (14, 17, 30). These
effects appear to be triggered by its interaction with cell surface
glycoprotein receptors (3, 18, 19, 25, 28). A number of bio-
chemical parameters for insulin/receptor interaction have been
characterized and compared in terms of properties of various
cells, such as growing and quiescent cells, normal and trans-
formed cells, and differentiating and nondifferentiating cells
(2, 13, 24, 27). Furthermore, recent studies have indicated that
some form of compartmentalization or internalization occurs
during insulin's interaction with the receptor and that the
receptor-bound insulin undergoes a substantial degradation or
processing that is associated with subcellular organelles (1, 9,
10, 16). Insulin has recently been shown to alter proliferation
rates in Cloudman S-91 mouse melanoma cells in culture,
presumably by altering intracellular levels of cyclic AMP (20).
In this paper we describe the binding of insulin to cellular
receptors and the fate of cell-bound insulin at various phases
of the cell cycle in the synchronized cell populations of Cloud-
man S-91 melanoma.
MATERIALS AND METHODS
Cell Cultures
Cloudman S-9l mouse melanoma cells (Clone M-3, CCL 53.1) were obtained
from the American Type Culture Collection. Cells were grown in Ham's F10
nutrient medium supplemented with 2% fetal calfserum, 10% horse serum (Flow
Laboratories, Inc., Rockville, Md.) and antibiotics (penicillin, 100 U/ml, and
streptomycin, 100 trg/ml; Microbiological Associates, Walkersville, Md.) under
5% C02/95% airat 37°C. Cellswere synchronized bythe mitoticshakeoffmethod
described previously (8). In this procedure no coercive agents such as colchicine
are used to restrict cell-cycle traverse. Melanocyte-stimulating hormone (MSH)
was prepared in the laboratory ofDr. Victor Hruby and kindly provided to us.
Assay for 1251-labeled Insulin Binding
Cells grown in 60-mm-diameter plastic culture dishes were placed on ice and
washed with ice-cold binding (B)-buffer, 2 ml each. TheB-buffer contained 100
mM HEPES (Sigma Chemical Co., St. Louis, Mo.), pH 7.8, 120 mM NaCl, 1.2
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MM MgS04, 5 mM KCI, 10 mM glucose, l mM EDTA, 15 mM Na-acetate and
1% bovine serum albumin (Sigma Chemical Co.; RIA grade). These stock
solutions were kept frozen until use. I ml of B-buffer containing 1 X l0-'° M (or
1 X 10-" M) 'z'Mabeled porcine insulin (New England Nuclear, Boston, Mass.;
100 tLCi/pg) was added and the cells were incubated at 15° or 37°C for various
times. Theplates were washed three times with ice-cold B-buffer, 3 ml each. The
cells were then solubilized with I ml of 0.5 N NaOH. Aliquots (0.9 ml) were
mixed with 7 ml each of Riafluor (New England Nuclear) and acidified with 75
Ill of 6 N HCI. Radioactivity was counted in a Packard liquid scintillation
spectrometer (Packard Instrument Co., Downers Grove, Ill.). To measure non-
specific binding, 1 Id of unlabeled porcine insulin (1 mg/ml of0.01 N HCl, 26.6
U/mg; Elanco Products Co., Indianapolis, Ind.) was added immediately before
the addition of radioactive insulin. Nonspecific binding thus measured ranged
from 10 to 15%, which was subtracted from the total binding to estimate specific
binding.
Location of Cell-bound Insulin
This was analyzed by the following two methods: (a) Cell cultures were
incubated with `z.I-insulin under the conditions described in the previous para-
graph. After incubation at 37°C for various times, the cells were placed on ice,
washed three times with ice-cold B-buffer, and then treated with 0.2 M acetic
acid (pH 2.5) containing 0.5 M NaCl at 4°C for 6 min to remove cell-surface
bound "'I-insulin (11). The remaining "'I-insulin that had been compartment-
alized or internalized was solubilized in 1 N NaOH. (b) The cells that had been
treated with 'z5I-insulin and washed extensively with B-buffer at 4°C were
dissolved in 0.4 ml of a solution consisting of4Murea, I M acetic acid and 0.1%
Triton X-100. The cell lysate was clarified by centrifugation at 30,000 g for 30
min. The supernate was loaded onto the top of a column (0.9 X 28 cm) of
Sephadex G-75 that had been equilibrated with the same solution (16, 26).
Fractions of 0.4 ml each were collected, and radioactivity was counted as before.
Recovery of the cell-bound radioactivity in the effluent of the column ranged
from 95 to 100%. Thevoid volume and the elution position ofnative insulin were
determined by a separate running with blue dextran 2000 and "'I-insulin,
respectively.
To test the involvement of lysosomal proteases in insulin degradation, cells
were incubated with 0.1 mM chloroquine for 20 min at 23°C before insulin
binding assay. In this case, the B-buffer contained 0.1 mM chloroquine. To
remove surface-bound 'z5I-insulin, cells were incubated with trypsin (l mg/ml)
in B-buffer for 5 min at 37°C.
Cell Counting and Size Analysis
Cells were removed from the culture dishes by conventional trypsinization
and counted by Electrozone/Celloscope (Particle Data, Inc., Elmhurst, Ill.).
Counting variations were 5-10% on duplicate dishes, and the frequency of live
cells was usually 95-100%, which was determined by the trypan blue dye
exclusion test. Cell size distribution and mean volume estimation were carried
out according to the Particle Data instruction manual, using standard polystyrene
beads (Duke Scientific Corp., Palo Alto, Calif).
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Fig. 1A shows the time-course of binding of 1251-insulin to
Cloudman S-91 mouse melanoma cells in monolayer at 15°
and 37°C. At 15°C, maximal binding was reached after incu-
bation for 60 min and the amount of cell-bound radioactivity
remained constant, whereas at 37°C a rapid decrease of cell-
bound radioactivity was observed after reaching a maximum
at 10-30 min. This is a well-documented phenomenon in
various cell types exposedto either insulin or other polypeptide
hormones and has been attributed to the consequence of
internalizationfollowed by intracellular degradation and secre-
tion (4, 7, 9, 15, 16). Fig. 1 B shows the distribution of radio-
activity into the cell exterior and cell interior during the initial
30-min incubation at 37°C. For this, cells were incubated with
1251-insulin, washed to remove unbound hormone as described
in Fig. 1A, and then treated with acetic acid (pH2.5)containing
0.5 M NaCI at 4°C. The radioactivity released by this acid
treatment is derived mainly from the cell surface, and the
remaining acid-resistant counts are of intracellular origin,
namely, internalized insulin, as is evidenced below. In Fig. 1 B,
1251-insulin was initially found in an acid-soluble fraction but
after 10 min there was a decrease in this fraction with a
concomitant increase in the acid-resistant fraction, indicating
a transition from acid solubility to acid resistance. Analysis of
the acid-soluble fraction on Sephadex G-75 gel filtration (16,
26) revealed that >90% of the radioactivity eluted with native
insulin. The acid-resistant fraction was found to be a mixture
ofiodotyrosine-containing oligopeptidesandintact 1251-insulin,
ofwhichthe ratio (degraded/intact) increasedwith time. When
cells that had been incubated with '251-insulin for 30 min were
treated with trypsin, >90% ofthe acid-soluble counts were lost,
whereas acid-resistant counts remained unchanged (Table I).
Contrary to this, the acid-resistant counts were substantially
reduced when cells were treated with chloroquine, a lysosomal
protease inhibitor, for 20 min before insulin binding. It is noted
that chloroquine treatment increasedoverall bindingofinsulin.
All these data seem to support the idea that the insulin bound
to the surface receptors of mouse melanoma cells undergoes
internalizationand is subject to intracellulardegradative proc-
essing, perhaps through a lysosomal pathway. Approximately
two-thirds of the cell-bound insulin is processed by 30 min at
37°C.
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FIGURE 1
￿
(A) Time-course of 1251-insulin binding to mouse mela-
noma cells at 15° (O) and 37°C ("). 1251-insulin concentration was
1 x 10-9 M. (B) Time-course of processing of cell-bound insulin .
Cells were incubated with '25 1-insulin, at 37°C for the indicated
time, washed to remove unbound hormone, and then treated with
0.2 M acetic acid/0.5 M NaCl. 0, Total; A, acid resistant; 0, acid
soluble.
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TABLE I
Effects of Trypsin and Chloroquine on Insulin Binding and
Processing
"'I-insulin bound, cpm/dish
Cloudman 5-91 melanoma cells were incubated with I x 10-9 M' z51-insulin
at 37°Cfor 30 min.
" Insulin-treated cells were incubated with trypsin (1 mg/ml) for 5 min at
37°C.
$ Cells were treated with chloroquine (0,1 mM) for 20 min at 23°C before
insulin-binding assay.
To the best of our knowledge, insulin-binding activity has
notbeen reported in termsofthecell cycle. Because Cloudman
S-91 melanoma cells are easily synchronized by mitotic
shakeoff (8) and because these cells exhibit reasonably high
activity of insulin binding (Fig. 1 and Table I), we undertook
the cell-cycle analysis of insulin binding to surface receptors.
In these experiments, mitotic cells were inoculated into fresh
medium, and insulin binding was measured at various times.
We have previously shown that the length of the Cloudman
mouse melanoma cell cycle is 24 h and that the lengths of the
cell-cycle phases are: G1, 10.0 h; S, 8.0 h; G2, 2.0 h; and M, 4.0
h (8). The time intervals used to measure insulin binding were
thus picked to coincide with these cell-cycle phases. The results
in Table II clearly show that insulin receptors are persistently
present during the cell cycle. It is noted, however, that cells at
S phase exhibit the highest insulin-binding activity, which is
two to four times higher than in G1-phase cells (note relative
activity shown in parentheses in Table II). The difference in
insulin-binding activity is more accurately demonstrated when
cell surface area (estimated from cell-volume analysis) is con-
sidered. It should be notedthat cells 26 h aftermitotic shakeoff,
namely in second cycle of G,, possess insulin-binding activity
similar to that in the first G, phase. This findingeliminates the
possibility that insulin in serum may have masked receptors
during the initial G, period afterinoculation and inhibited 125I-
insulin binding until it was exhausted from the medium.
It has recently been shown that insulin and MSH act antag-
onistically to control cell proliferation of Cloudman S-91 mel-
anoma cells (20). Therefore, we examined the possibility that
MSH binding to cellular receptors might modulate the levels
of availableinsulin receptors. As is shownin Table III, insulin-
binding activity was not influenced by pretreatment ofthecells
with MSH for three time periods up to 24 h.
Next, we analyzed the fate of the cell-bound insulin during
the cell cycle. For this, cells treated with 1251-insulin at 37°C
for various times were washed extensively with binding buffer
to remove unbound insulin, dissolved in a solution containing
urea, acetic acid, and Triton X-100, and subjected to gel
filtration on Sephadex G-75. Previous studies in which similar
conditions were used have revealed the presence of intact
insulin and two new radioactive components, one with a
smaller and one with a larger molecular weight than that of
insulin (15, 23,25). Fig. 2 shows elution profiles ofradioactivity
resulting from the 1251-insulin bound to the melanoma cells
that are at G,, S, and G2, respectively. The majority of cell-
bound radioactivity eluted at the position corresponding to the
insulin marker (peak II) at 5 and 10 min. This peak was
greatest for every phase at 10 min and declined at 30 min. The
Treatment Total binding Acid-soluble Acid-resistant
None (control) 4,020 1,440 2,580
Trypsin* 2,339 86 2,253
Chloroquine$ 4,830 3,910 920TABLE II
Insulin-binding Activity of Mouse Melanoma Cells at Various Phases of Cell Cycle
Cells were incubated at 15°C for 60 min with 1 x 10-9 M '251-insulin. For details, see Materials and Methods. nt, not tested.
* Mean cell volume was determined by an Electrozone/Celloscope (see Materials and Methods) .
$ Average of insulin-binding activity was normalized to cell surface area, which was calculated from the mean cell volume.
TABLE III
Insulin-binding Activity of Mouse Melanoma Cells after
Treatment with MSH
Insulin binding, % of input counts/10 6 cells
Preincubation
￿
With MSH
￿
Without MSH
Cells were grown in the presence of 1 x 10-7 M MSH for the time indicated
and then incubated with 1 x 10-e M ' 251-insulin at 15°C for 60 min under the
conditions of the binding assay.
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FIGURE 2 Gel-filtration patterns of 1251-insulin bound to mouse
melanoma cells at the indicated cell phase. Cells were incubated at
37°C with 1251-insulin (1 X 10-9 M) as described under Materials
and Methods. At the indicated times, cells were washed with ice-
cold buffer to remove unbound insulin, dissolved in 4 M urea, 1 M
acetic acid, and 0.1% Triton X-100, and subjected to gel filtration on
Sephadex G-75. Void volume was fraction 12 ; elution position of
1251-insulin was fraction 24 ; total column volume was fraction 35.
Distribution of the cell-bound 1251-insulin into peak's 1, 11, and III is
indicated as percent of the total radioactivity recovered .
radioactive component that eluted just before the position of
the total column volume (peak III) corresponds to the iodo-
tyrosine-containing oligopeptides (16, 26), which must be of
intracellular origin, because (a)otherwise this wouldhave been
removed during extensive washing on ice, (b) the material in
this peak III was accumulated during 10-30 min, whereas
intact insulin in peak II decreased, (c) the peak III materials
were the major component found in the insulin-treated cells
that had been incubatedwith trypsin to remove surface-bound
insulin in a manner similar to that in Table I, (d) the appear-
ance of peak III has been shown to be substantially reduced
after treatment of cells with inhibitors of lysosomal proteases,
such as chloroquine. A significant fraction of the cell-bound
radioactivity is processed as a high molecular weight compo-
nent that elutes at the void-volume position (peak I). This has
been observed by us and others (16, 26)and is postulated to be
insulin irreversibly bound to cellular components including
insulin receptors. It is interesting to note that peak I material
is accumulated more in the cells at S phase at 30 min. Taking
all these data together, we conclude that an internalization of
the cell-bound insulin and its processing, perhaps through the
lysosomal degradation pathway, occurs during the entire cell
cycle.
DISCUSSION
The investigation ofpeptide hormone bindingto surfacerecep-
tors throughout the cell cycle has received little attention. The
appearance of surface receptors for nerve growth factor in
neuroblastoma cells is confined to the GI-S border (22). Re-
ceptors for MSH are expressed only in the G2 phase (28), and
the stimulation of tyrosinase in these cells by MSH is similarly
confined to the G2 phase (29). More recent studies, however,
have shown that MSH can induce tyrosinase activity in any
phase of the cell cycle, a finding that suggests that MSH
receptors are present throughout the cell cycle (8).
The results presented here have not only demonstrated the
presence of insulin receptors in Cloudman S-91 melanoma cell
cultures but have shown that the level of expression of these
surface receptors is regulated throughout the cell cycle. Insulin
is required for the growth of one line (M2R) of mouse mela-
noma cells in a chemically defined medium (12). However, it
has been observed that insulin concentration as low as 10-1°M
can retard growth rates of Cloudman S-91 melanoma cell
cultures (20). Concentrations of 10-e M were reported to arrest
proliferation completely (20). It was suggested that insulin
exerts its inhibitory effects by lowering cyclic AMP levels (20).
Because the inhibitory effect of insulin on cell growth was
shown to be antagonized by exposure of insulin-treatedcellsto
MSH (20), we investigated the effect of MSH on insulin
binding. We noted, however, no change in binding capacity.
The data at 2-h incubation (Table III) may exclude the possi-
bility that loss of insulin receptors is transient and is promptly
recovered to the steady-state level. Because insulin apparently
lowers cyclic AMP levels and suppresses, to some extent, the
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h
Corresponding
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Insulin-binding
Exp. I
ability, %
Exp. II
of input counts/10 6
Exp. III
cells
Average
Relative
cell
volume*
Insulin-binding
ability per cell
surface$
0 M nt nt 0.67 (0.7) 0.7 nt
4.5 G, 0.57 (1.0) 0.71 (1.0) 0.91 (1 .0) 1.0 1.0 1 .0
14 S 1.38 (2.4) 2.82 (4.0) 2.44 (2.6) 3 .0 1.6 2.2
19 G2 0.64 (1 .1) 1 .10 (1.6) 2,01 (2.2) 1 .6 1.6 1.2
26 G, (2nd) 0.54 (1 .0) 0.44 (0.6) 1 .71 (1.9) 1 .2 1 .3 1.0
with MSH
h
(A) (B) Ratio (A/B)
2 0.72 0.68 1 .05
7 0.76 0.67 1.14
24 0.70 0.67 1 .07stimulation of cyclic AMP production by MSH, it is possible
that insulin lowers the level of expressed MSH receptors. It is
also possible that insulin action in melanoma cells proceeds by
a mechanism distal to the initial hormone-surface receptor
binding event.
Recent evidence suggests apossible role forpeptidehormone
internalization in mediating various cellular responses (1, 4,
16). We have noted here that insulin is internalized in mela-
noma cells, and our results suggest that the hormone begins to
undergo degradation within 30 min after receptor binding. It
is therefore possible that, before degradation, insulin exerts its
cellular effects or that even after30 minenough intact hormone
is available to effect the cellular response, or that degradation
products function as a second messenger.
Our finding that the level of expression of insulin receptors
is regulated throughout the cell cycle, being highest at S and
lowest during G, phase, suggests a possible role for cell-cycle
traverse in regulating hormonal responsiveness. This observed
difference in insulin binding during the cell cycle could be
physiologically important only if the level of binding in G, is
insufficient to maximally affect the cell growth. The reported
presence of "spare receptors" for insulin as well as for other
peptide hormones suggests that a maximal cellular response
can occur without maximal receptor binding (4, 5, 15, 23).
Thus, if the melanoma cell response to insulin is maximal in
G, cells, then the importance of theincreased levelof hormone
binding in S to cellular regulation is questionable. It would,
however, be important to study whether increase of insulin
binding at S phase occurs because of a change in the number
of receptors or in a receptor's affinity.
We have recently observed that exposure of melanoma cells
to insulin results in a decrease not only in basal tyrosinase
activity but also in the level of MSH-induced enzyme activity
(our unpublished observation). Studies are now in progress to
determine whether this inhibitory effect of insulin occurs
throughout the cell cycle or is confined to a particular phase,
for example, S.
The possibility that the presence of functional receptors at
particular phases of the cell cycle represents another regulatory
control point for the cellular response to hormonal stimulation
remains to be investigated.
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